Argenx Se (ARGX) Receivables - Other (2017 - 2025)
Argenx Se's (ARGX) quarterly Receivables - Other came in at $171000.0 in Q2 2025, down 99.7% YoY from $57.5 million in Q2 2024, and down 96.98% on a QoQ basis from $5.7 million in Q4 2024.
Argenx Se (ARGX) Receivables - Other (2017 - 2025) Analysis & Trends
Argenx Se (ARGX) has 9 years of Receivables - Other data on file, last reported at $171000.0 in Q2 2025.
- Quarterly Receivables - Other fell 99.7% year-over-year to $171000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $171000.0 (down 99.7% YoY) and the FY2024 annual result came in at $5.7 million, up 188.69% from the prior year.
- Receivables - Other eased to $171000.0 in Q2 2025, from $5.7 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $57.5 million in Q2 2024 to a low of $171000.0 in Q2 2025.
- A 5-year average of $13.8 million and a median of $2.0 million in 2023 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2024 — Receivables - Other surged 188.69% — and 2025, when it plunged 99.7%.
- Tracing ARGX's Receivables - Other over 5 years: stood at $864000.0 in 2021, then gained by 18.63% to $1.0 million in 2022, then soared by 91.41% to $2.0 million in 2023, then soared by 188.69% to $5.7 million in 2024, then plunged by 96.98% to $171000.0 in 2025.
- The last three Receivables - Other figures came in at $171000.0 (Q2 2025), $5.7 million (Q4 2024), and $57.5 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 171,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Dec 31, 2024 | 5.66 Mn |
| Dec 31, 2024 | 5.66 Mn |
| Jun 30, 2024 | 57.51 Mn |
| Jun 30, 2024 | 57.51 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Jun 30, 2023 | 29.56 Mn |
| Jun 30, 2023 | 29.56 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Dec 31, 2021 | 864,000.00 |
| Dec 31, 2021 | 864,000.00 |
| Dec 31, 2020 | 5.54 Mn |
| Dec 31, 2020 | 5.54 Mn |
| Dec 31, 2019 | 3.82 Mn |
| Dec 31, 2019 | 3.82 Mn |
| Jun 30, 2019 | 292,146.16 |
| Jun 30, 2019 | 292,146.16 |